Table 1 Assessment of treatment response
From: Infliximab therapy in refractory sarcoidosis: a multicenter real-world analysis
Organ/Disease manifestation | Assessment method | Definition of treatment success |
|---|---|---|
Lung | Spirometry | Increase in absolute FVC or FEV1 by > 10% or No change in FVC or FEV1 (± 10% from baseline) |
Skin | Clinical images | 50% improvement in skin lesions in comparison to baseline images |
Upper airway | Nasolaryngoscopy & CT | Improvement in structural change on serial exam and imaging |
CNS | MRI | Improvement or no progression from baseline imaging |
Peripheral lymph nodes | Clinical assessment | Resolution of lymphadenopathy |
GI | Clinical assessment and laboratory | Resolution of symptoms and normalization of laboratory testing |
Eye | Clinical assessment and eye exam | Resolution of symptoms and improvement of abnormalities on serial eye exam |
Joint | Clinical assessment and laboratory | Resolution of symptoms and normalization of laboratory testing |